BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) delivery of peptides and proteins. It is a cutting-edge and mature solution for oral formulations not only for peptides, but also small molecules, novel protein scaffolds, nucleotides, domain antibodies.
Products, services, technology
Key products for outlicensing are :
- Sublingual exenatide
- Sublingual liraglutide
- Sublingual insulin+
- low dose sublingual IL2 for auto-immune disorders
BioLingus is open to partner its platform technology for development of products with other companies (eg peptides)